Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3763
+0.02597.39%
Post-market: 0.3761-0.0002-0.05%19:30 EDT
Volume:128.46K
Turnover:47.28K
Market Cap:14.21M
PE:-0.86
High:0.3900
Open:0.3630
Low:0.3512
Close:0.3504
52wk High:1.98
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.24
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-9.11
PE(LYR):-0.86

Loading ...

Company Profile

Company Name:
Neurosense Therapeutics Ltd
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
17
Office Location:
Building B,11 HaMenofim Street,Herzliya,Israel
Zip Code:
4672562
Fax:
- -
Introduction:
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Directors

Name
Position
Alon Ben Noon
Chief Executive Officer and Director
Mark Leuchtenberger
Chairman of the Board
Cary Claiborne
Independent Director
Christine Pellizzari
Independent Director
Revital Mandil Levin
Independent Director
Roy Golan
Independent Director

Shareholders

Name
Position
Alon Ben Noon
Chief Executive Officer and Director
Hagit Binder
Chief Operating Officer
Or Eisenberg
Chief Financial Officer
Niva Russek Blum
Chief Technology Officer